Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34519770.
- Also identified by DOI 10.1001/jamanetworkopen.2021.26344 and PMC identifier 8441592.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cohort study examines safety and antibody responses after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant (HSCT).
Medical subject headings
- Antibody Formation
- BNT162 Vaccine